Help Advance Research for Cognitive Impairment

Evaluating an investigational medication for adults with schizophrenia who experience memory, attention, or decision-making challenges.

See If You Qualify

Location

Austin, Texas

Study Type

Inpatient Study

Duration

32-Day Stay

Population

Ages 18–55

About the Study

Advancing mental health discovery.

Community Clinical Research is conducting a randomized study to evaluate the efficacy and safety of an investigational medication, KYN-5356.

The research focuses on helping adults with schizophrenia manage cognitive symptoms such as memory challenges, attention deficits, and decision-making difficulties.

What to Expect

A structured 32-day research stay

Inpatient Care

32-day continuous stay at the Austin research clinic.

Medical Testing

Cognitive testing, heart monitoring (ECG), and bloodwork.

Who Can Participate?

Adults aged 18 to 55
Schizophrenia diagnosis (≥1 year)
Clinically stable on medication
Willing to complete the 32-day stay

Benefits & Compensation

Up to $6,600 for completion.

Participants who qualify and complete the study may receive compensation up to $6,600 for their time and travel. All study-related procedures are provided at no cost.

See if you qualify for
this Austin-based study

Help us evaluate new options for cognitive symptoms in schizophrenia.

See If You Qualify

Frequently Asked Questions

The study evaluates the safety and effectiveness of KYN-5356 as an adjunctive treatment for cognitive impairment associated with schizophrenia.

Yes, this specific protocol requires a 32-day continuous inpatient stay at our research facility in Austin, Texas.

Yes, your information is protected and handled in strict accordance with HIPAA and medical privacy regulations.